Document Detail

Monitoring of dabigatran therapy using Hemoclot(®) Thrombin Inhibitor assay in patients with atrial fibrillation.
MedLine Citation:
PMID:  25103614     Owner:  NLM     Status:  Publisher    
Dabigatran, a new direct thrombin inhibitor, achieves strong anticoagulation that is more predictable than warfarin. Nevertheless, a patient on dabigatran therapy (DT) may suffer from thrombotic or bleeding events. The routine monitoring of DT is not recommended, and standard coagulation tests are not sensitive enough for the assessment of DT activity. The aim of this study was to examine the clinical usefulness of the Hemoclot(®) Thrombin Inhibitor (HTI) assay in the assessment of dabigatran plasma levels in patients with non-valvular AF. Nineteen patients (12 men, 7 women) on DT were included in this preliminary prospective observational study. Dabigatran was administrated twice daily in a two dose regimens: 150 mg (5 patients) and 110 mg (14 patients). Blood samples were taken for the assessment of trough and peak levels of dabigatran. Dabigatran concentrations were measured with the HTI assay. The average dabigatran trough level was 69.3 ± 55.5 ng/ml and the average dabigatran peak level was 112.7 ± 66.6 ng/ml. The dabigatran trough plasma concentration was in the established reference range in 15 patients and the dabigatran peak plasma concentration was in the established reference range in 9 patients, respectively. Despite the fact that the activated partial thromboplastin and thrombin times were generally changed (prolonged), these tests failed to identify the patients with too low or too high dabigatran concentrations. The study confirmed the high sensitivity of the HTI assay for the assessment of dabigatran plasma levels. When compared to standard coagulation tests, the HTI is a more suitable assay for the monitoring of patients treated with dabigatran. Monitoring of DT may be beneficial in selected patients; however, further studies will be needed for the final clarification of this issue.
Matej Samoš; Lucia Stančiaková; Jela Ivanková; Ján Staško; František Kovář; Miroslava Dobrotová; Peter Galajda; Peter Kubisz; Marián Mokáň
Related Documents :
24633024 - Serum albumin levels predict clinical outcomes in chronic kidney disease (ckd) patients...
23816834 - Acute encephalopathy with unilateral cortical-subcortical lesions in two unrelated kind...
24821934 - Spontaneous intracranial hypotension with camptocormia.
23480804 - Liver fibrosis in patients with non-alcoholic fatty liver disease: diagnostic options i...
20945614 - Ataxia-telangiectasia in a patient presenting with hyper-immunoglobulin m syndrome.
14630494 - Are there physical risk factors for psychogenic non-epileptic seizures in patients with...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-8-8
Journal Detail:
Title:  Journal of thrombosis and thrombolysis     Volume:  -     ISSN:  1573-742X     ISO Abbreviation:  J. Thromb. Thrombolysis     Publication Date:  2014 Aug 
Date Detail:
Created Date:  2014-8-8     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9502018     Medline TA:  J Thromb Thrombolysis     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Antithrombotic therapy before, during and after transcatheter aortic valve replacement (TAVR).
Next Document:  Transcriptional control of floral anthocyanin pigmentation in monkeyflowers (Mimulus).